These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 8656271)

  • 61. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
    Hanson DS; Leggette CT
    Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
    [No Abstract]   [Full Text] [Related]  

  • 62. Autoimmunity aids survival in melanoma.
    Senior K
    Lancet Oncol; 2006 Apr; 7(4):289. PubMed ID: 16598882
    [No Abstract]   [Full Text] [Related]  

  • 63. [Adjuvant therapy of malignant melanoma].
    Hauschild A; Volkenandt M
    Ther Umsch; 1999 Jun; 56(6):324-9. PubMed ID: 10420815
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Economic analyses of benefit from interferon-alpha 2B in high-risk melanoma: trade-offs between completeness, simplicity and clarity.
    Hillner BE; Kirkwood JM
    Eur J Cancer; 1997 Aug; 33(9):1345-6. PubMed ID: 9337671
    [No Abstract]   [Full Text] [Related]  

  • 66. [Melanoma during pregnancy].
    Pagès C; Misset JL; de Kerviler E; Bavoux F; Fernandez H; Viguier M
    Ann Dermatol Venereol; 2012 Apr; 139(4):298-304; quiz 296-7, 306-7. PubMed ID: 22482486
    [No Abstract]   [Full Text] [Related]  

  • 67. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma.
    Wheatley K; Ives N; Hancock B; Gore M
    J Clin Oncol; 2002 Oct; 20(19):4120-1; author reply 4121-2. PubMed ID: 12351611
    [No Abstract]   [Full Text] [Related]  

  • 69. [Current therapy of carcinoma of the skin].
    Dummer R; Goldinger SM; Sailer E; French LE
    Ther Umsch; 2010 Sep; 67(9):447-52. PubMed ID: 20806173
    [TBL] [Abstract][Full Text] [Related]  

  • 70. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Results of adjuvant interferon study in WHO melanoma programme.
    Cascinelli N; Bufalino R; Morabito A; Mackie R
    Lancet; 1994 Apr; 343(8902):913-4. PubMed ID: 7908370
    [No Abstract]   [Full Text] [Related]  

  • 73. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 74. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
    Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
    Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Modern tumor therapy as seen in melanoma].
    Dummer R; Nestle FO; Burg G
    Praxis (Bern 1994); 1996 Dec; 85(50):1609-14. PubMed ID: 8999490
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Melanomas reveal their nakedness: uncovered by interferon alfa.
    Arbiser JL; Bonner MY
    Arch Dermatol; 2009 May; 145(5):587-8. PubMed ID: 19451506
    [No Abstract]   [Full Text] [Related]  

  • 77. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.
    Cole BF; Gelber RD; Kirkwood JM; Goldhirsch A; Barylak E; Borden E
    J Clin Oncol; 1996 Oct; 14(10):2666-73. PubMed ID: 8874325
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diagnosis and management of high-risk and metastatic melanoma.
    Hollis G; Recio A; Schuchter L
    Semin Oncol Nurs; 2003 Feb; 19(1):32-42. PubMed ID: 12638379
    [TBL] [Abstract][Full Text] [Related]  

  • 79. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

  • 80. Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment.
    Ascierto PA; Mozzillo N; Caracò C; Parasole R; Palmieri G; Melucci MT; Botti G; Castello G
    Ann Oncol; 2000 Nov; 11(11):1504. PubMed ID: 11142495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.